Author Archives: Marisa Wexler MS

Ziritaxestat Clinical Trials Discontinued

Galapagos NV and Gilead Sciences are discontinuing all clinical trials with the investigational medication ziritaxestat. This includes the long-term extension of the Phase 2a NOVESA trial in scleroderma, as well as the Phase 3 ISABELA program in idiopathic pulmonary fibrosis (IPF). The decision is based on…

TMB-003 Therapy to Reduce Scarring Wins FDA Orphan Drug Designation

Scleroderma treatment TMB-003, which aims to improve patients’ quality of life by reducing the scarring that characterizes the autoimmune disorder, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). This designation is awarded to investigational therapies intended to improve treatment for rare diseases,…

Documentary ‘Beyond Breathless’ Highlights Interstitial Lung Disease

A new documentary, “Beyond Breathless,” will showcase the journey of those affected by interstitial lung disease (ILD) through the real experiences of people living with rare lung diseases, their loved ones, and healthcare professionals. The documentary, by pharmaceutical company Boehringer Ingelheim, will premier at noon EST Saturday (Dec. 5) on…